Table 2.
Follow-up visit data and nephrotic syndrome status for study subjects.
| Patient ID | Indication | Parameter | Baseline | After final treatment | 1M F/U | 3M F/U | 6M F/U | 12M F/U | 24M F/U | Notes | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCH001 | Patient 1 | Post-transplant | NS | NS | Partial | Partial | Partial | Partial | Withdrawal | Withdrawal after 6-month F/U | ||
| UPCR (g/g) | 44.33 | 13.02 | 17.43 | 12.81 | 17.51 | |||||||
| SCR (mg/dl) | 0.8 | 0.4 | 0.6 | 0.6 | 0.6 | |||||||
| eGFR (ml/min/1.73 m2) | 62.2 | 125.4 | 83.6 | 83.0 | 83.9 | |||||||
| LDL (mg/dl) | 60 | 71 | 269 | 344 | 498 | |||||||
| NDE001 | Patient 2 | Primary FSGS | NS | NS | NS | NA | NS | Withdrawal | Withdrawal after 3-month F/U | |||
| UPCR (g/g) | 8.11 | 3.84 | Not performed | 6.27 | ||||||||
| SCR (mg/dl) | 0.7 | 0.7 | 0.7 | 0.8 | ||||||||
| eGFR (ml/min/1.73 m2) | 89.4 | 91.0 | 89.7 | 78.7 | ||||||||
| LDL (mg/dl) | 212 | 30 | 181 | 189 | ||||||||
| NDE002 | Patient 3 | Primary FSGS | NS | NS | NS | NS | Partial | Complete | Complete | Par | 24-month F/U completed | |
| UPCR (g/g) | 6.33 | <5.0 | 3.33 | 0.90 | 0.18 | 0.08 | 0.36 | |||||
| SCR (mg/dl) | 0.8 | 0.4 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | |||||
| eGFR (ml/min/1.73 m2) | 84.9 | 172.2 | 112.9 | 114.3 | 98.3 | 100.3 | 100.4 | |||||
| LDL (mg/dl) | 345 | 23 | 96 | 70 | 78 | 45 | 62 | |||||
| NDE003 | Patient 4 | Post-Transplant Recurrence | NS | Not performed | Withdrawal | Withdrawal after final treatment (w/o F/U) | ||||||
| UPCR (g/g) | 5.05 | |||||||||||
| eGFR (ml/min/1.73 m2) | 95.8 | |||||||||||
| LDL (mg/dl) | 73 | |||||||||||
| NDE004 | Patient 5 | Primary FSGS | NS | NS | Excluded | Excluded from the study | ||||||
| UPCR (g/g) | 8.16 | |||||||||||
| SCR (mg/dl) | 0.7 | |||||||||||
| eGFR (ml/min/1.73 m2) | 72.9 | |||||||||||
| LDL (mg/dl) | N/A | |||||||||||
| NDE005 | Patient 6 | Post-Transplant Recurrence | NS | NS | NS | Withdrawal | Withdrawal after final treatment (w/o F/U) | |||||
| UPCR (g/g) | 19.52 | 25.58 | ||||||||||
| eGFR (ml/min/1.73 m2) | 76.6 | 47.1 | ||||||||||
| LDL (mg/dl) | 64 | 47 | ||||||||||
| ACH001 | Patient 7 | Primary FSGS | NS | NS | Excluded from the study | |||||||
| UPCR (g/g) | 1.05 | Excluded | ||||||||||
| SCR (mg/dl) | 1.9 | |||||||||||
| eGFR (ml/min/1.73 m2) | 39.8 | |||||||||||
| LDL (mg/dl) | 165 | |||||||||||
| ACH002 | Patient 8 | Primary FSGS | NS | NS | NS | Partial | Complete | Partial | Complete | Complete | 24-month F/U completed | |
| UPCR (g/g) | 1.98 | 0.71 | 0.39 | 0.10 | 0.42 | 0.17 | 0.16 | |||||
| SCR (mg/dl) | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | |||||
| eGFR (ml/min/1.73 m2) | 170.7 | 170.3 | 129.1 | 129.8 | 130.1 | 132.2 | 109.4 | |||||
| LDL (mg/dl) | 126 | 26 | 98 | 91 | 115 | 179 | 95 | |||||
| ACH003 | Patient 9 | Primary FSGS | NS | NS | NS | NS | NS | NS | NS | Withdrawal after 12-month F/U | ||
| UPCR (g/g) | 1.81 | 3.48 | 2.67 | 2.11 | 4.01 | 3.78 | Withdrawal | |||||
| SCR (mg/dl) | 1.2 | 1.2 | 1.4 | 1.2 | 1.4 | 2.2 | ||||||
| eGFR (ml/min/1.73 m2) | 60.0 | 60.0 | 51.9 | 60.9 | 52.5 | 33.9 | ||||||
| LDL (mg/dl) | 96 | 21 | 98 | 86 | 138 | 143 | ||||||
| ACH004 | Patient 10 | Primary FSGS | NS | Excluded | Excluded from the study | |||||||
| UPCR (g/g) | 0.08 | |||||||||||
| SCR (mg/dl) | 1.2 | |||||||||||
| eGFR (ml/min/1.73 m2) | 158.5 | |||||||||||
| LDL (mg/dl) | 103 | |||||||||||
| ACH006 | Patient 11 | Post-Transplant Recurrence | NS | NA | ||||||||
| UPCR (g/g) | Not performed | Under treatment | ||||||||||
| SCR (mg/dl) | 0.7 | |||||||||||
| eGFR (ml/min/1.73 m2) | 72.7 | |||||||||||
| LDL (mg/dl) | 132 | |||||||||||
| LLU001 | Patient 12 | Post-Transplant Recurrence | NS | NS | NS | NS | Withdrawal | Withdrawal after 1-month F/U | ||||
| UPCR (g/g) | 4.78 | 3.01 | 3.66 | |||||||||
| eGFR (ml/min/1.73 m2) | 84.7 | 103.8 | 129.8 | |||||||||
| LDL (mg/dl) | N/A | 4 | 81 | |||||||||
| LLU002 | Patient 13 | Primary FSGS | NS | NS | NS | NS | Withdrawal | Withdrawal after 1-month F/U | ||||
| UPCR (g/g) | 4.1 | 5.21 | 4.58 | |||||||||
| SCR (mg/dl) | 0.3 | 0.3 | 0.3 | |||||||||
| eGFR (ml/min/1.73 m2) | 153.0 | 159.1 | 160.8 | |||||||||
| LDL (mg/dl) | N/A | 7 | 110 | |||||||||
| LLU003 | Patient 14 | Post-Transplant Recurrence | NS | NS | NS | Partial | Partial | Partial | Partial | Partial | 24-month F/U completed | |
| UPCR (g/g) | 1.09 | 1.66 | 1.49 | 0.70 | 0.67 | 0.37 | 0.34 | |||||
| eGFR (ml/min/1.73 m2) | 78.0 | 13 | 65.3 | 69.3 | 69.3 | 69.3 | 71.7 | |||||
| LDL (mg/dl) | 44 | 13 | 100 | 78 | 86 | 115 | 103 | |||||
| HDV001 | Patient 15 | Primary FSGS | NS | NA | NA | Withdrawal after final treatment (w/o F/U) | ||||||
| UPCR (g/g) | Not performed | Not performed | Withdrawal | |||||||||
| SCR (mg/dl) | 0.7 | 0.6 | ||||||||||
| eGFR (ml/min/1.73 m2) | 83.2 | 98.8 | ||||||||||
| LDL (mg/dl) | 56 | 27 | ||||||||||
| CHS001 | Patient 16 | Primary FSGS | NS | NS | NA | NA | NS | NS | NS | 12-month F/U completed | ||
| UPCR (g/g) | 5.42 | Not performed | Not performed | 12.51 | 8.83 | 2.77 | ||||||
| SCR (mg/dl) | 0.9 | 0.6 | 0.4 | 0.3 | 0.3 | 0.3 | ||||||
| eGFR (ml/min/1.73 m2) | 60.3 | 89.5 | 134.2 | 179.0 | 183.0 | 191.4 | ||||||
| LDL (mg/dl) | N/A | 15 | 389 | 370 | 350 | 163 | ||||||
| CHS002 | Patient 17 | Primary FSGS | NS | NS | NS | NS | Withdrawal | Withdrawal after 1-month F/U | ||||
| UPCR (g/g) | 28.04 | 8.33 | 38.4 | |||||||||
| SCR (mg/dl) | 0.3 | 0.4 | 0.5 | |||||||||
| eGFR (ml/min/1.73 m2) | 216.1 | 163.5 | 130.8 | |||||||||
| LDL (mg/dl) | >DL*4 | >DL*4 | 14 | |||||||||
NS, nephrotic syndrome; F/U, follow up; UPCR, urine protein to creatinine ratio; SCR, serum creatinine; eGFR, estimated glomerular filtration rate; LDL, low density lipoprotein.